Datamonitor Healthcare estimates that in 2019, there were approximately 121.1 million seropositive prevalent cases of celiac disease and 48.0 million prevalent cases of biopsy-proven celiac disease worldwide.
Author: Pharma Intelligence
Publisher: Datamonitor Healthcare
Published: 08 September 2022
Number of pages:23
This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, clinical trials, probability of success, and a 10-year disease prevalence forecast.
Datamonitor Healthcare estimates that in 2021, there were approximately 123.4 million seropositive prevalent cases of celiac disease, and 49.1 million prevalent cases of biopsy-proven celiac disease worldwide.
Pooled seroprevalence is estimated to be 1.4%, and the pooled prevalence of biopsy-proven disease is estimated to be 0.7% worldwide.
Biopsy-confirmed celiac disease is 1.5 times more common in females than in males, and approximately two times more common in children than in adults.
The greatest proportion of industry-sponsored drugs in active clinical development for celiac disease are in Phase II. Therapies in development for celiac disease target interleukin-15/interleukin-15 receptor and gluten. Pipeline drugs for celiac disease are administered via the oral, intravenous, and subcutaneous routes.
The overall likelihood of approval of a Phase I autoimmune/immunology asset is 11.8%, and the average probability a drug advances from Phase III is 66.3%. Drugs, on average, take 9.5 years from Phase I to approval in the overall autoimmune/immunology space.
All clinical trials for celiac disease have been in either Phase I or Phase II.
The US has the highest number of celiac disease clinical trials globally. Clinical trial activity in the celiac disease space is dominated by completed trials. 9 Meters Biopharma has the highest number of completed clinical trials for celiac disease, with six trials.
9 Meters Biopharma leads industry sponsors with the highest overall number of clinical trials for celiac disease.
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
12 PIPELINE DRUGS
16 PROBABILITY OF SUCCESS
17 CLINICAL TRIAL LANDSCAPE
18 Sponsors by status
19 Sponsors by phase
19 Recent Events
LIST OF FIGURES
12 Figure 1: Overview of pipeline drugs for celiac disease in the US
12 Figure 2: Pipeline drugs for celiac disease, by company
13 Figure 3: Pipeline drugs for celiac disease, by drug type
13 Figure 4: Pipeline drugs for celiac disease, by classification
16 Figure 5: Probability of success in the autoimmune/immunology pipeline
17 Figure 6: Clinical trials in celiac disease
17 Figure 7: Top 10 drugs for clinical trials in celiac disease
18 Figure 8: Top 10 companies for clinical trials in celiac disease
18 Figure 9: Trial locations in celiac disease
19 Figure 10: Celiac disease trials status
19 Figure 11: Celiac disease trials sponsors, by phase
LIST OF TABLES
10 Table 1: Prevalent cases of celiac disease, by definition, 2021
11 Table 2: Prevalence of celiac disease, by definition
14 Table 3: Pipeline drugs for celiac disease in the US
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.